Breast Cancer News and Research

Latest Breast Cancer News and Research

Genome epigenetic analysis reveals new ways to detect and treat breast cancer

The most comprehensive analysis yet of the epigenetic modifications present in breast cancer has revealed potentially important new ways to detect and treat the disease, Belgian researchers have reported.

5 May 2011

Clinical study: Celecoxib drug may treat breast cancer

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

5 May 2011

New poll: 57% of women believe mammograms should start at age 40

A U.S. health task force stunned much of the medical world and many women in November 2009 by recommending that most women didn't need to get their first mammogram until age 50.

5 May 2011

Researchers discover new mechanism by which BRCA1 gene mutations can induce breast cancer

Two researchers from the Centre for Genomic Regulation in Barcelona have discovered a new mechanism by which mutations in gene BRCA1 can induce breast cancer.

5 May 2011

Researchers identify regulatory protein that can inhibit cancer metastasis

A protein capable of halting the spread of breast cancer cells could lead to a therapy for preventing or limiting the spread of the disease.

5 May 2011

Breast shields can protect women from radiation exposure during CT exams

The use of breast shields is the technique of choice to protect the breasts of women from radiation exposure while undergoing chest CT examinations, according to a new study.

4 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

FDA clears Sectra's digital mammography system

Women in the US will now have the same opportunity as million of European women already have; to undergo mammography with significantly lower radiation dose. This is the result of FDA's clearance of the Swedish IT and medical technology company Sectra's digital mammography system, Sectra MicroDose Mammography.

4 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

Top-line results from Lymphoseek NEO3-09 Phase 3 study in breast cancer, melanoma

Neoprobe Corporation, a diversified developer of innovative oncology diagnostic products, today announced top-line results from its Lymphoseek NEO3-09 study.

4 May 2011

Tecnologie Avanzate, Naviscan sign deal to distribute PET scanner in Italy

Naviscan, Inc., the leader in 3D Molecular Breast Imaging, has entered into a distribution agreement with Tecnologie Avanzate s.r.l. to market and service Naviscan's high-resolution organ-specific PET scanner in Italy.

3 May 2011

McMaster receives new Canadian Cancer Society grants for groundbreaking research

Three cancer studies led by Hamilton researchers are among 52 new research projects worth close to $22 million announced by the Canadian Cancer Society.

3 May 2011

Statins can help reduce lung damage in severe abdominal sepsis

Statins may be best known for their ability to reduce cholesterol, but a research report appearing in the May 2011 issue of the Journal of Leukocyte Biology shows that these same drugs could also play a crucial role in the reduction of lung damage resulting from severe abdominal sepsis and infection.

3 May 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011

USPSTF recommendations negatively impact yearly mammograms among 40-49 year old women

Two new studies reveal that the United States Preventative Services Task Force's recommendation to no longer screen women ages 40-49 for breast cancer using mammograms has begun to negatively affect the number of yearly mammograms performed in this age group and thus decrease the benefits of early detection.

2 May 2011

Alcohol and raised cancer risk: Report

These numbers come from the Cancer Council analysis that reveals the number of cancer cases caused by long-term drinking in Australia is far higher than previously thought, following strong international evidence of its link to a broader range of cancer types.

1 May 2011

MarginProbe System meets its primary endpoints: Dune Medical Devices

Dune Medical Devices, Inc. today announced that the landmark, 664-patient pivotal trial evaluating the MarginProbe System met its primary endpoints. The MarginProbe System provides surgeons with a real time, intraoperative technology to detect microscopically-positive margins on excised tissues.

30 Apr 2011

Mammography screening can benefit women under age 50

Screening mammography benefits women between 40 and 49 years of age, and excluding this population from annual exams under the revised Preventative Service Task Force mammography guidelines would negatively impact survival, according to research presented this week at the American Society of Breast Surgeons Annual Meeting.

30 Apr 2011

IMPAKT 2011 conference to highlight new breast cancer studies

"The presentations at this year's IMPAKT reveal the innovative and diverse approaches that investigators are taking to identify the most encouraging new agents both before clinical evaluation and in early clinical studies. These range from ideas for novel clinical designs to the development of more sensitive and specific biomarkers and to data sharing that allows a more objective assessment of compounds prior to commitment of major clinical resources."

30 Apr 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011